Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140783 · ClinicalTrials.gov registry record · Phase 3
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
A Phase 3 study of Vision Disorders and Vision Loss Night, sponsored by Ocuphire Pharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07140783: Recruiting Phase 3 study of Vision Disorders and Vision Loss Night, sponsored by Ocuphire Pharma.
NCT07140783 is a Phase 3 study of Vision Disorders and Vision Loss Night that is actively recruiting participants, run by Ocuphire Pharma. The registered enrollment target is 200 participants, above the 34-participant average among 5 other Vision Disorders trials with a reported enrollment target (488% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07140783, a Phase 3 study of Vision Disorders and Vision Loss Night, is actively recruiting participants, sponsored by Ocuphire Pharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions. It will also learn about the safety of Phentolamine Ophthalmic Solution. The main questions it aims to answer are: Researchers will compare Phentolamine Ophthalmic Solution to a placebo (a look-alike substance that contains no drug) to see if Phentolamine Ophthalmic Solution works to improve vision in low light conditions. Participants will: Take Phentolamine Ophthalmic Solution or a placebo drop every day for 2 weeks Visit the clinic once every week for 2 weeks for checkups and tests Keep a diary of when they instill the study medication each evening
Primary Outcome
To evaluate the efficacy of POS to improve mLCVA in subjects with previous keratorefractive surgery
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 0.75% Phentolamine Ophthalmic Solution
Study Locations (20)
California
- Global Research Management - Glendale
- Gordon Schanzlin New Vision - La Jolla
- Eye Research Foundation - Newport Beach
- California Eye Specialists Medical Group - Pasadena
- NVISION Clinical Research - San Diego
- Scripps Poway Eyecare and Optometry - San Diego
- Wolsten and Goldberg Eye Assoc. - Torrance
Arizona
- Arizona Eye Care - Chandler
- Carrot Eye Center - Mesa
- Eye Doctors of Arizona - Phoenix
- MRB Eye Care Consultants - Scottsdale
Florida
- Glaucoma Specialist of South Florida - Delray Beach
- Segal Drug Trials - Delray Beach
Illinois
- Wyse Eyecare - Northbrook
- Virdi Eye Clinic - Rock Island
Kansas
- Durrie Vision - Overland Park
- Kannarr Eye Care - Pittsburg
Massachusetts
- Eye Health Vision Center - South Dartmouth
- Northeast Eye Research Associates - Woburn
North Carolina
- Oculus Research - Garner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-09-02 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
What NCT07140783 shows while recruiting
NCT07140783 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 34-participant average among 5 other Vision Disorders trials with a reported enrollment target (488% higher).
The record links to 2 conditions, with Vision Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07140783 names 20 study sites across 7 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07140783 about?
NCT07140783 is a clinical study titled "OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity". The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions. It will also learn about the safety of Phentolamine Ophthalmic Solution. The main questions it aims ...
What is the current status of trial NCT07140783?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-09-02. Estimated completion is 2026-03.
What conditions does trial NCT07140783 study?
This clinical trial studies the following conditions: Vision Disorders, Vision Loss Night.
What interventions are being tested in trial NCT07140783?
The interventions under investigation include: Placebo (DRUG), 0.75% Phentolamine Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07140783?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140783 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vision Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ACTIVE NOT RECRUITING · Phase 1
-
Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation
ACTIVE NOT RECRUITING · NA
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Natural History Study of CEP290-Related Retinal Degeneration
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI